Efficacy Study of Pharmacist Intervention on Medication-related Problems in Hemodialysis Patients
Effects of Pharmacist on Medication-related Problems in Hemodialysis Patients: a Randomized,Controlled, Double-blind Study
The investigators propose that pharmacist interventions would reduce the amount of unresolved medication-related problems in hemodialysis patients.
Condition:Hemodialysis patients
Intervention:Behavioral,Pharmacist intervention
Study Design:Randomized Allocation
Control: Active Control
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
연구 개요
상세 설명
Introduction:
End stage renal disease (ESRD) incidence in Taiwan ranked first and prevalence ranked second in the world from 2002 to 2005. Several foreign researches had reported that hemodialysis (HD) patients often require 12 medications to treat 5 to 6 comorbid conditions. Besides, ESRD is a lifelong disease and rates of compliance may diminish overtime. Thus, HD patients may be at particular risk for drug related problems, durg-drug interactions and noncompliance. Our aim is to analysis the effect of pharmacist in medication-related problems in ambulatory hemodialysis patients.
Methods:
This study is a randomized double-blind, active controlled trial. The investigators will invite and communicate with HD patients to find medication -related problems. After pharmacist evaluation, pharmacist will do pharmaceutical interventions to resolve medication-related problems, drug-drug interactions etc. in experimental group. In the active control group, pharmacist in this study will not do pharmaceutical interventions. The investigators will monitor each patient in a two-week period for medication-related problems.
Our primary outcome is the amount of unresolved medication-related problems in each group after two weeks. Blind outcome assessor will evaluate the amount of unresolved medication-related problems in each case as well as compliance in these patients after two weeks.
The investigators suppose that clinical pharmaceutical intervention will reduce the amount of unresolved medication-related problem in experimental group. On the other hand, patients without clinical pharmaceutical intervention will have more unresolved medication-related problems.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Tainan, 대만, 701
- 아직 모집하지 않음
- Sin-Lau hospital
-
연락하다:
- Hung-Yi Chen, MS
- 전화번호: 1040 06-2748316
- 이메일: lawrence_chern@yahoo.com.tw
-
연락하다:
- Li-Pin Chou, MD
- 전화번호: 5175 06-2748316
- 이메일: slh10@sinlau.org.tw
-
수석 연구원:
- Hung-Yi Chen, MS
-
Tainan city, 대만
- 모병
- Tainan Sin-Lau Hospital
-
연락하다:
- Hung-Yi Chen, MS
- 전화번호: 1040 06-2748316
- 이메일: lawrence_chern@yahoo.com.tw
-
연락하다:
- Li-Pin Chou, MD
- 전화번호: 5175 06-2748316
- 이메일: slh10@sinlau.org.tw
-
수석 연구원:
- Hung-Yi Chen, MS
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 20-96 years old hemodialysis patient taking medications prescribed by nephrologists.
Exclusion Criteria:
- Patients who refused informed consent
- Cognitive impaired
- unable to talk or hearing disability
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: clinical pharmacist intervention
|
Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
|
|
간섭 없음: usual care
Patients randomized to usual care group will receive routine review of medication by outpatient department pharmacists and nurse.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
amount of unsolved medication-related problems in each group
기간: 14 days
|
Clinical pharmacist provide pharmaceutical care in experimental group in order to reduce medication-related problems.
With pharmaceutical care, we suppose that amount of unsolved medication-related problems will less than the control group.
|
14 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Patient self-reported medication compliance
기간: 14 days after recruitment
|
14 days after recruitment, outcome assessor will record patient self-reported medication compliance. 1 score means almost noncompliance,while 5 score means that patient takes almost every medication.
|
14 days after recruitment
|
|
pharmaceutical care satisfaction
기간: 14 days after recruitment
|
From 1 score to 5 scores, 1 score means that patient is very unsatisfied with pharmaceutical care in the past 14 days.
5 scores means that patient is very satisfied with pharmaceutical care in the past 14 days.
|
14 days after recruitment
|
|
adverse events
기간: 14 days after recruitment
|
An adverse event is any adverse change in health or side effect that occurs in a person who participates in our clinical trial while the patient is receiving the medications prescribed by physician.
|
14 days after recruitment
|
|
knowledge about medication
기간: 14 days after recruitment
|
Patient self-reported knowledge about medication.
From 1 score to 5 scores, as the score increase, it means that patients know more information about his medication.
|
14 days after recruitment
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Hung-Yi Chen, Sin-Lau hospital
간행물 및 유용한 링크
일반 간행물
- Yang WC, Hwang SJ; Taiwan Society of Nephrology. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant. 2008 Dec;23(12):3977-82. doi: 10.1093/ndt/gfn406. Epub 2008 Jul 15.
- Schmid H, Schiffl H, Lederer SR. Pharmacotherapy of end-stage renal disease. Expert Opin Pharmacother. 2010 Mar;11(4):597-613. doi: 10.1517/14656560903544494.
- Manley HJ, Bailie GR, Grabe DW. Comparing medication use in two hemodialysis units against national dialysis databases. Am J Health Syst Pharm. 2000 May 1;57(9):902-6. doi: 10.1093/ajhp/57.9.902. No abstract available.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
pharmaceutical care에 대한 임상 시험
-
China Medical University Hospital완전한
-
The Third Xiangya Hospital of Central South University아직 모집하지 않음샤르코-마리-투스병(CMT)
-
University of AlbertaUniversity Hospital Foundation완전한
-
Boston Medical CenterNational Institute on Minority Health and Health Disparities (NIMHD); Center for Community...완전한비만 | 천식 | 혈압 | 아동 발달 | 건강관리 활용 | 아동학대 | 의료 격차 | 기본적인 미충족 사회적 욕구미국
-
The Hospital for Sick Children모집하지 않고 적극적으로
-
New York UniversityIndiana University; Moi University완전한
-
University Health Network, Toronto모병림프종 | 림프 증식 장애 | 유방암 1기 | 유방암 2기 | 대장암 2기 | 대장암 3기 | 유방암 3기 | 대장암 1기 | 두경부암 3기 | 유방암, 0기 | 두경부암 1기 | 두경부암 2기캐나다
-
Emory UniversityFoundation for Physical Therapy, Inc.완전한